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The interaction of lecithin-cholesterol acyltransferase (LCAT)
with apolipoprotein A-I (apoA-I) plays a critical role in high-
density lipoprotein (HDL)maturation.We previously identified
a highly solvent-exposed apoA-I loop domain (Leu159–Leu170)
in nascent HDL, the so-called “solar flare” (SF) region, and pro-
posed that it serves as an LCAT docking site (Wu, Z., Wagner,
M. A., Zheng, L., Parks, J. S., Shy, J. M., 3rd, Smith, J. D.,
Gogonea, V., and Hazen, S. L. (2007) Nat. Struct. Mol. Biol. 14,
861–868). The stability and role of the SF domain of apoA-I in
supporting HDL binding and activation of LCAT are debated.
Here we show by site-directed mutagenesis that multiple resi-
dues within the SF region (Pro165, Tyr166, Ser167, and Asp168) of
apoA-I are critical for both LCAT binding to HDL and LCAT
catalytic efficiency. The critical role for possible hydrogen bond
interaction at apoA-I Tyr166 was further supported using recon-
stituted HDL generated from apoA-I mutants (Tyr1663 Glu or
Asn), which showed preservation in both LCAT binding affinity
and catalytic efficiency. Moreover, the in vivo functional signif-
icance ofNO2-Tyr166-apoA-I, a specific post-translationalmod-
ification on apoA-I that is abundant within human atheroscle-
rotic plaque, was further investigated by using the recombinant
protein generated from E. coli containing amutated orthogonal
tRNA synthetase/tRNACUA pair enabling site-specific insertion
of the unnatural amino acid into apoA-I. NO2-Tyr166-apoA-I,
after subcutaneous injection into hLCATTg/Tg, apoA-I/mice,
showed impaired LCAT activation in vivo, with significant
reduction in HDL cholesteryl ester formation. The present
results thus identify multiple structural features within the sol-
vent-exposed SF region of apoA-I of nascent HDL essential for
optimal LCAT binding and catalytic efficiency.
Apolipoprotein A-I (apoA-I), the major protein component
of high-density lipoprotein (HDL), transports lipids and also
serves as a protein scaffold for numerous HDL-associated pro-
tein interactions. The HDL particle is responsible for facilitat-
ing reverse cholesterol transport, a multistep process that
removes cholesterol from peripheral tissues and ultimately
from the body in feces. To promote its cholesterol carrier func-
tions, apoA-I exists in multiple forms throughout the reverse
cholesterol transport process. Initially, lipid-free or lipid-poor
apoA-I becomes lipidated, generating the nascentHDL particle
via the ATP-binding cassette transporter type 1 (ABCA1)4
(1–4). Although capable of facilitating reverse cholesterol
transport, subsequent maturation of the HDL particle into a
cholesteryl ester-laden spherical particle substantially increases
the capacity of theHDL particle to carry cholesterol cargo. Lec-
ithin-cholesterol acyltransferase (LCAT) is the primary enzyme
responsible for catalyzing the maturation of nascent HDL into
spherical HDL by catalyzing esterification of free cholesterol
(1). Fielding and colleagues (5) first showed that apoA-I within
nascent HDL stimulates LCAT activity (5–7). The mechanism
by which LCAT facilitates HDL maturation at the structural
level is still unknown.
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Genetic studies confirm critical roles for both LCAT and
apoA-I in lipid transport (8). Subjects with genetic deficiency of
LCAT are characterized by markedly reduced HDL cholesterol
levels (9).Whereas LCAT is clearly involved in the reverse cho-
lesterol transport process and delivery of sterols to adrenal tis-
sues, its role in atherosclerosis development is still debated
(10–16). Naturally occurring mutations in human apoA-I that
are associated with low LCAT activities and low levels of HDL
cholesterol have been extensively reviewed (13, 17, 18). These
naturally occurring mutations, along with a variety of site-spe-
cific mutation and deletion studies, have suggested that multi-
ple regions on apoA-I are important for LCAT interactions
with HDL (6–8, 19–23).
Using hydrogen-deuterium exchange mass spectrometry
analyses, we previously identified a peptide region (Leu159–
Ala180) within apoA-I of nascent HDL with a markedly
enhanced hydrogen-deuterium exchange rate, indicating a pre-
dominantly open and solvent-accessible conformation (24).
A functional role for this region as an LCAT interaction site
was suggested based upon additional hydrogen-deuterium
exchange mass spectrometry results, which showed reductions
in deuterium incorporation rate within the overlapping apoA-I
peptide region Leu159-Leu170 of nascent HDL in the presence
versus absence of LCAT (24). We called this a “solar flare” (SF)
region of apoA-I because it presumably represented a highly
solvent-exposed protruding loop on the anti-parallel apoA-I
chain in a nascent HDL particle (24). We reported that both
point mutation of Tyr166 of apoA-I (i.e. Y166F), a residue that
we showed is a target for oxidative post-translational modifica-
tion within human atherosclerotic plaque (25, 26), and peptide
competition assays, using a synthetic peptide whose sequence
spans a portion of the SF region, further corroborated a role for
this domain within apoA-I in LCAT interaction (24, 26). How-
ever, in contrast to our report that apoA-I Y166F affects LCAT
activity by as much as 70% reduction (24), others reported a
more minor (20%) reduction of LCAT activity of Y166F and
questioned the significance of this residue and the SF region as
a docking site for LCAT interaction (13). In more recent stud-
ies, we developed recombinant apoA-I with site-specific 3-ni-
trotyrosine incorporation only at position 166 of apoA-I using
an evolved orthogonal nitro-Tyr-aminoacyl-tRNA synthetase/
tRNACUA pair. This enabled in vitro studies with recombinant
human apoA-I incorporating this unnatural amino acid exclu-
sively at position 166 to evaluate functional effects of NO2-
Tyr166-apoA-I within reconstituted HDL and illustrated a
reduced capacity to activate LCAT in vitro (26); however, the
impact of this post-translational modification on LCAT-medi-
ated maturation of HDL in vivo has not yet been explored.
There thus exists debate of the significance of the SF region
of apoA-I for HDL/LCAT interaction, both as a docking site
and in the activation of LCAT for particle maturation. We
hypothesize that within the SF region of apoA-I, some of the
amino acids are important for maintaining the structure of
the loop and thus play a role in LCAT docking, whereas the
same or others may impact presentation of the HDL particle
lipid to LCAT, impacting catalytic activity. Herein we explore
in detail critical structural and functional relationships within
this proposed LCAT interaction loop of apoA-I to define the
role(s) for individual amino acids in supporting both optimal
LCAT binding to the nascent HDL particle and optimal LCAT
catalytic efficiency.We also explore for the first time the in vivo
functional impact of post-translational modification of apoA-I
Tyr166 through nitration, which is enriched in human athero-
sclerotic lesions, using a humanized mouse model of apoA-I/
LCAT interaction and infusion of endotoxin-free recombinant
NO2-Tyr166-apoA-I.
Experimental Procedures
Materials and General Methods—All chemicals were from
Sigma, and all solvents wereHPLC grade unless otherwise indi-
cated. [3H]cholesterol was fromPerkinElmer Life Sciences. The
purity of recombinant apoA-I forms was analyzed by SDS-
PAGE, and the purity and size of reconstitutedHDL containing
recombinant human apoA-I (rHDL) was estimated using both
4–20% non-denaturing equilibrium gel electrophoresis using
precast gels (Bio-Rad) and dual-beam light scattering. The size
of nascent HDL was determined by comparison with protein
standards of known Stokes diameter (GE Healthcare). Choles-
terol efflux (total and ABCA1-dependent) activity was mea-
sured using RAW264.7 cells in 48-well dishes according to
established laboratory procedures (27). HDL cholesterol mass
(both free and cholesteryl ester forms) were quantified using
mass spectrometry as described previously (28). All mouse
studies were performed under protocols approved by the Insti-
tutional Animal Care and Use Committee at the Cleveland
Clinic.
Mice—Transgenic human LCAT mice (hLCATTg/Tg) back-
crossed onto a C57Bl/6J background (10 generations) were
provided by Dr. J. S. Parks and were described previously (10).
ApoA-I knock-out mice (apoA-I/) were purchased from
Jackson Laboratory (Bar Harbor, ME) and have been back-
crossed for 10 generations onto a C57Bl/6J background.
Human LCATTgmice that are apoA-I-deficient (hLCATTg/Tg,
apoA-I/) were generated by breeding hLCATTg/Tgmice on a
C57Bl/6J background (10 generations) with apoA-I/mice
on a C57Bl/6J background (10 generations).
Site-directed Mutagenesis and Expression of Recombinant
and Mutant Forms of Human ApoA-I—Recombinant human
apoA-I mutants carrying a single substitution (P165A, Y166X
(where X represents Ala, Glu, Phe, or Asn), S167A, D168A,
Y192F, or Y192L) were created by using the QuikChange
mutagenesis kit (Stratagene, La Jolla, CA). The template was
the plasmid pET20b, containing the mature human apoA-I
sequence, that had been codon-optimized for Escherichia coli
expression as described previously (28). The QuikChange
primers were designed by the online QuickChange Primer
Design Program and further synthesized by IDT (Coralville,
IA). The sequence of eachmutated cDNAwas verified by auto-
mated DNA sequence analysis before it was transformed into
E. coli strain BL21(DE3)pLysS for the expression of the recom-
binant proteins. Wild-type and mutant apoA-I forms were
purified to homogeneity by nickel-nitrilotriacetic acid affinity
chromatography as described (29). For studies where apoA-I
was injected intomice for in vivo LCAT activitymeasurements,
recombinant human apoA-I andNO2-Tyr166-apoA-Iwere gen-
erated as described previously (26) but using ClearColi
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BL21(DE3), an E. coli strain genetically modified to be func-
tionally deficient in generating endotoxin, as described recently
for alternative apoA-I mutants (28). Endotoxin levels in all
recombinant apoA-I were confirmed to be nominal (0.5
EU/mg/ml protein) by a Limulus amebocyte lysate assay
(Charles River Laboratories, Wilmington, MA) under condi-
tionswhere positive controls showed detection of trace levels of
LPS (1.0 EU/mg/ml protein) added to apoA-I.
Preparation and Characterization of rHDL—rHDL contain-
ing the indicated recombinant apoA-I was prepared using the
sodium cholate dialysis method (30), with a startingmolar con-
centration ratio of 100:10:1 of 1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine (POPC), free cholesterol, and apoA-I,
respectively. All rHDL preparations were further purified using
a Sephacryl-S300 column (GE Healthcare). Pooled fractions of
rHDL were concentrated using Amicon Ultra-15 10k centrifu-
gal filter devices (EMDMillipore, Billerica, MA). The amounts
of phospholipids and cholesterol in purified rHDLpreparations
were determined by amicrophosphorus assay and a cholesterol
enzymatic assay kit (Stanbio Laboratory, Boerne, TX), respec-
tively, as described previously (31). The content of apoA-I
within rHDL preparations was quantified by UV absorbance at
A280 nm. Extinction coefficients used for WT and mutant
apoA-I forms were individually calculated using the ProtParam
tool, a program provided freely by the Swiss Institute of Bioin-
formatics. The 280 used was 32,430 mol1 cm1 for WT
apoA-I and the mutants P165A, S167A, and D168A and 30,940
mol1 cm1 for the apoA-I mutants Y166F, Y166A, Y166E,
Y192F, and Y192L. Before use of UV spectroscopy for apoA-I
quantification in all mutant apoA-I forms, the accuracy of this
approach was verified (for WT and a few different mutant
apoA-Is) by stable isotope dilution HPLC with on-line tandem
mass spectrometry (LC/MS/MS) by quantifying the amounts of
leucine, tyrosine, and phenylalanine in apoA-I in acid hydroly-
sates using heavy isotope-labeled leucine, tyrosine, and pheny-
lalanine as internal standards.
LCATKinetics Assay—Recombinant human LCAT (hLCAT)
was purified from the culturemedium of CHO cells transfected
with hLCAT plasmid as described (32). The rHDL used as sub-
strate for LCAT assaywas prepared as described above butwith
the incorporation of a trace amount of [3H]cholesterol (45
Ci/mmol; GE Healthcare). The reaction mixtures contained
0–35 M HDL cholesterol and 20 ng of purified His-tagged
hLCAT in a buffer composed of 10 mM sodium phosphate, pH
7.4, 1mMEDTA, 150mMNaCl, 2mM-mercaptoethanol, 0.6%
fatty acid-free bovine serum albumin. Reactions were carried
out in triplicate at 37 °C under argon. LCAT activity was deter-
mined by calculating the conversion efficiency of [3H]choles-
terol into [3H]cholesteryl ester after lipid extraction of reaction
mixture followed by thin layer chromatography and scintilla-
tion counting (24). The extent of cholesterol esterification was
kept below 5% of free cholesterol levels to maintain first order
kinetics. The fractional cholesterol esterification rate was
expressed as nmol of cholesteryl ester formed/h/ng of LCAT.
Apparent Vmax and Km values were determined from Hanes-
Woolf plots of cholesterol substrate concentration divided by
the cholesteryl ester formation rate versus HDL cholesterol
substrate concentration using GraphPad Prism version 4
(GraphPad Software, La Jolla, CA).
HDL/LCAT Binding Studies—Full time course kinetic deter-
mination of kon, koff, and apparent equilibrium dissociation
constants (Kd) for rHDL interaction with recombinant hLCAT
were determined using surface plasmon resonance (SPR) spec-
troscopy (6). Measurements of apparent Kd between hLCAT
and rHDLwere performed using a BIAcore 3000 SPR biosensor
(BIAcore, AB, Uppsala, Sweden) following themethods of Jin et
al. (33) with modification. Briefly,8000 relative units of poly-
clonal antibody against apoA-I (Biodesign, Saco, ME) was
immobilized on a CM5 sensor chip through primary amino
groups using reactive esters as per the manufacturer’s direc-
tions. rHDL was captured on the sensor chip through interac-
tion with antibody against apoA-I by injecting 7 M rHDL at a
flow rate of 15 l/min in 10 mM PBS buffer (pH 7.4) into the
flow cell. To determine theKd between rLCATand rHDL, vary-
ing concentrations of recombinant hLCAT (500–2000 nM)
were flowed over immobilized rHDL in binding buffer (10 mM
PBS, pH 7.4) at a flow rate of 20 l/min. Lipoprotein-depleted
serum (5%, v/v) was used to reduce nonspecific binding when
measuring HDL/LCAT binding affinities of NO2-Tyr166-
apoA-I versus wild-type apoA-I. At the end of each cycle, sur-
faces of the sensor chipswere regenerated by injection of 15mM
HCl at the same flow rate. The apparent Kd was obtained by
fitting background-subtracted SPR binding data to the 1:1
bindingwith a drifting baselinemodel in BIAevaluation version
4.0 (BIAcore, AB, Uppsala, Sweden).
In Vivo LCAT Activity Measurement—Recombinant apoA-I
proteins (NO2-Tyr166-apoA-I versus apoA-I (WT), 4 mg/ani-
mal) were injected subcutaneously into hLCATTg/Tg, apoA-
I/ mice, and serum samples were collected at the indicated
time points. ApoB-containing lipoprotein fractions were pre-
cipitated, and then cholesterol and cholesteryl ester content of
recovered HDL was quantified by stable isotope dilution gas
chromatography with on-line mass spectrometry, as described
previously (28).
Statistical Analyses—Statistically significant differences
were determined by Student’s t test. Statistical differences are
reported when p was 0.05. All experimental results are pre-
sented as means S.D. of at least triplicate analyses.
Results
Characterization of Mutant ApoA-I and rHDL Particles—In
addition to the wild type (WT) apoA-I protein, we initially gen-
erated a series of mutant recombinant human apoA-I forms
(P165A, Y166F, S167A, and D168A) to investigate how these
four adjacent amino acids within the SF region participate in
LCAT interaction (docking and activation). Because of the con-
troversy regarding whether Tyr166 of apoA-I serves as a func-
tionally important residue in LCAT interaction (24, 34) and its
involvement as a target for oxidative post-translational modifi-
cation enriched in human atheroma (26, 35), we generated
additional alternativemutations of this residue (Y166A, Y166E,
and Y166N) to further investigate its unique potential role in
LCAT docking and activation. Finally, we also mutated apoA-I
Tyr192, an alternative target for oxidative post-translational
modification enriched in human atheroma (35), to serve as a
A Loop Region in ApoA-I Critical for LCAT Activity
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pathophysiologically relevant alternative residue that is pre-
sumed to be localized distant from the LCAT docking site. All
apoA-I mutants were purified by nickel affinity chromatogra-
phy to apparent homogeneity as judged by SDS-PAGE (Fig.
1A). To test the impact of mutation of these individual SF res-
idues toHDLdocking by LCAT, rHDLswere prepared contain-
ing each individual recombinant mutant apoA-I form. All
rHDLs were prepared with a starting molar ratio of phospho-
lipid (POPC)/cholesterol/apoA-I of 100:10:1, and then each
rHDL was purified and characterized chemically and by native
PAGE, as described under “Experimental Procedures.” Analy-
ses of rHDL incorporating individual apoA-I mutants demon-
strated that each rHDL particle preparation was monodis-
persed, as determined by dual-beam light scattering, and9.6
nm in diameter, as analyzed by 4–20% equilibrium native gel
electrophoresis (Fig. 1B). The chemical compositions of the
rHDL preparations were also remarkably similar, as shown in
Table 1, with similar amounts of POPC and cholesterol, except
for Y166F and D168A, which had slightly higher content of
POPCwithin the HDL particles (25–30%). Analysis of the puri-
fied rHDL preparations by CD spectroscopy similarly shows no
differences betweenWT and each of the mutant apoA-Is, indi-
cating no significant change in their -helical content. Thus,
detailed chemical, sizing, and CD spectroscopy characteriza-
tion suggested that the overall secondary structures of the WT
versusmutant apoA-I forms within rHDL were similar.
Mutations in the SF Region of ApoA-I Selectively Impact
LCAT but Not Cholesterol Efflux Activity—We first examined
the effects of residues within the SF region of apoA-I on cho-
lesterol efflux activity. Each lipid-free homogeneous apoA-I
mutant (WT versus P165A, Y166F, S167A, and D168A) was
individually incubated with cholesterol-loaded macro-
phages. As shown in Fig. 2, no apparent differences were
observed in either total cholesterol efflux activity (under
conditions of ABCA1 stimulation with 8-bromoadenosine
3,5-cyclic monophosphate) or ABCA1-dependent choles-
terol efflux activity.
Next, LCAT activation properties of rHDL were character-
ized using the recombinant particles generated with eitherWT
human apoA-I or the individual mutant apoA-I forms, includ-
ing P165A, Y166X (where X represents Ala, Glu, Phe, or N),
S167A, D168A, and Y192X (where X represents Phe or Leu).
Incubation of hLCAT with rHDL formed using the apoA-I
mutants P165A, Y166A, Y166F, S167A, and D168A all showed
significant decreases in LCAT activity (40–60%; Fig. 3A) com-
pared with WT. Interestingly, whereas the Y166A and Y166F
apoA-I mutants showed suppressed LCAT activation activity,
mutation of apoA-I Tyr166 to an amino acid residue capable of
forming a hydrogen bond (e.g.Y166E and Y166N) fully restored
LCAT activation capacity of rHDL particles produced with
those apoA-I (relative toWT; Fig. 3). These studies thus affirm
the importance of apoA-I Tyr166 in HDL for LCAT activation
and suggest involvement of this residue in either a hydrogen
bond or an ionic interaction with LCAT. In contrast to the
importance of residueswithin the SF region, rHDL formedwith
either apoA-I Y192F or Y192L mutant showed normal LCAT
activity (Fig. 3A).
To further evaluate the impact of each of the apoA-Imutants
on LCAT catalytic efficiency, more detailed LCAT enzyme
kinetics were performed. Table 2 shows the Km and Vmax for
each of the rHDL formed with the indicated apoA-I mutants.
Further, for illustrative purposes, Fig. 3B illustrates kinetic
studies for WT apoA-I versus two of the Tyr166 mutant forms.
FIGURE1.Characterizationof recombinantapoA-I andreconstitutednas-
cent HDL particles. Recombinant apoA-I (WT versus the indicated mutants)
were purified from E. coli by nickel-nitrilotriacetic acid affinity chromatogra-
phy, and nascent HDL particles were prepared using amodified cholate dial-
ysismethod at amolar ratio of 100:10:1 POPC/cholesterol/apoA-I. rHDL prep-
arations were further purified using a Sephacryl-S300 size exclusion column.
A, SDS-polyacrylamide gel analyses of purified recombinant apoA-I (WT and
indicated point mutants). B, native polyacrylamide gel analyses of reconsti-
tuted nascent HDL containing recombinantWT apoA-I or the indicated point
mutants.
TABLE 1
Characterization of reconstituted nascent HDL particles
Reconstituted nascent HDL particles from the indicated recombinant apoA-I forms
were prepared and isolated, and then the chemical composition of the particles was
determined as described under “Experimental Procedures.” The size of nascent
HDL particles was determined by comparison with the known diameter of globular
standard proteins on equilibrium native PAGE analysis. Results represent mean
S.D. of three independent HDL preparations.
HDL
Molar ratio Diameter
(native PAGE)POPC Cholesterol ApoA-I
nm
WT 89.3 4.8 9.7 0.5 1 9.6
P165A 107.7 3.2 8.1 0.1 1 9.6
Y166F 125.0 4.4 7.8 0.7 1 9.6
S167A 96.9 0.7 7.1 0.8 1 9.6
D168A 132.3 2.6 7.6 0.5 1 9.6
Y166A 115.3 3.9 9.8 0.3 1 9.6
Y166E 82.1 11.4 9.4 0.2 1 9.6
Y166N 99.4 3.2 8.5 0.1 1 9.6
Y192F 105.6 19.8 9.7 0.3 1 9.6
Y192L 83.4 6.7 10.4 0.3 1 9.6
A Loop Region in ApoA-I Critical for LCAT Activity
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BothVmax of Y166F andVmax of Y166A are 20% lower than that
of WT apoA-I, and the apparent Km values are about 2–6-fold
higher than that for WT (1.5 M) (i.e. with a higher Km, the
rHDLs harboring these mutant apoA-I are less effective at acti-
vating LCAT, and it takes a higher HDL concentration to
achieve half-maximal LCAT activity). In contrast, replacement
of Tyr166 with Glu or Asn only leads to slight changes ofKm and
Vmax. Replacement of apoA-I Asp168 with Ala also showed sig-
nificant reduction of Km of LCAT (3-fold), whereas P165A
and S167A showed a modest increase in Km. Besides the
observed changes of Km of the rHDL incorporating these
mutants, the reductions ofVmax were also observed with muta-
tion to the Tyr166 and other SF sites. The Vmax values of
mutants P165A, Y166A, Y166F, S167A, and D168A were all
30–60% lower than that ofWT,whereasY166E andY166Nhad
a Vmax similar to that of WT.
The overall catalytic efficiency (kcat) of LCAT-mediated con-
version of cholesterol to cholesteryl ester can be estimated by
the calculation of Vmax/Km. ApoA-I mutants P165A, Y166A,
Y166F, S167A, and D168A only retained 12–42% of the cata-
lytic efficiency of WT. Mutants Y166N and Y166E retained
much higher LCAT catalytic efficiency (80%) compared with
mutants Y166F and Y166A, which only retained 12–38% of
LCAT catalytic efficiency.
Mutations in the SF Region Impair HDL/LCAT Binding—To
further probe the underlying mechanism of impairment of
LCAT, catalytic efficiency caused by the mutations in the SF
region of apoA-I, SPR analyses were performed to determine
the Kd between hLCAT and rHDL formed with WT apoA-I
versus each of the apoA-I mutant forms (Fig. 4). To eliminate
the high background when HDLs were directly coated on the
chips, rHDL harboringWT or mutant apoA-I were tethered to
the chip by first coating the chip with goat anti-apoA-I anti-
body, coupling the indicated rHDL, and then varying concen-
trations of hLCAT flowed over the tethered rHDL. Results of
the binding studies reaffirmed the generalization that apoA-I
residues in the SF region are important for LCAT/HDL inter-
action (binding) (Table 3). Notably, we observed a direct corre-
lation between the strength of LCAT/HDL binding and LCAT
activation potential in the rHDL harboring each mutant. For
example, apoA-I mutants Y166A, Y166F, and D168A, which
FIGURE 2.Cholesterol efflux activities of nascent HDLs. A, total cholesterol
efflux activities of recombinant apoA-I (WT, P165A, Y166F, S167A, andD168A)
purified from E. coli. B, ABCA-I-dependent cholesterol efflux activities of
recombinant apoA-I (WT, P165A, Y166F, S167A, and D168A) purified from
E. coli. Cholesterol efflux activities were measured by incubating different
HDL with RAW264.7 cells in 48-well dishes according to established proce-
dures in thepresenceofABCA1 stimulationasdescribedunder “Experimental
Procedures.” Data shown represent the mean S.D. (error bars) of triplicate
experiments. p values were nonsignificant (NS) as determined by Student’s t
test.
FIGURE 3. LCATactivities of nascentHDL.A, LCAT activities of reconstituted
nascent HDL containing recombinant apoA-I (WT versus the different
mutants indicated) were measured as described under “Experimental Proce-
dures.” Note that Y166E/N and Y192F/L retain at least 80% of LCAT activities
comparedwithWT,whereas P165A, Y166A/F, S167A, andD168Aall exhibited
significant reduction in the ability to activate LCAT compared with WT. B,
Hanes-Woolf ([S]/V versus [S]) plots of nascent HDLs containing recombinant
apoA-Is (WT, Y166A, andY166E). Data shown represent themean S.D. (error
bars) of triplicate experiments. p values were determined by Student’s t test.
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showed 5-fold reduction in LCAT binding affinity, demon-
strated the highest LCAT Km and the greatest reduction in
LCAT catalytic efficiency. By comparison, apoA-I mutants
P165A and S167A only exhibit 2–3-fold reduction in LCAT
binding affinity and showed more modest elevation in Km and
loss of LCAT catalytic efficiency. Interestingly, apoA-Imutants
Y166E and Y166N, as well as both apoA-I Y192L and Y192F
mutants, which do not show reduction in LCAT activation
activity, also showed a Kd similar to that of WT apoA-I. The
restoration of LCAT/HDL binding affinity and LCAT catalytic
efficacy of apoA-I mutants Y166E and Y166N strongly suggests
that the loss of LCAT activation caused by the apoA-I Y166A or
Y166F mutation is at least partially due to the weaker binding
between LCAT and apoA-I within these rHDLs.
NO2-Tyr166-ApoA-I Exhibits Impaired LCAT Activity in
Vivo—Using a novel monoclonal antibody specific for NO2-
Tyr166-apoA-I and not native apoA-I, we recently showed that
post-translational modification of apoA-I through nitration of
Tyr166 is remarkably abundant and is observed in 1 in 12
apoA-Is recovered from human atherosclerotic lesions, yet it is
undetectable in normal aorta (26). We also developed recom-
binant apoA-I with site-specific 3-nitrotyrosine incorporation
only at position 166 using an evolved orthogonal nitro-Tyr-
aminoacyl-tRNA synthetase/tRNACUA pair and showed that
this abundantmodified apoA-I has reduced capacity to activate
LCAT in vitro when incorporated into rHDL (26). To further
probe the underlying mechanism of impairment of LCAT cat-
alytic efficiency caused byHDLharboring an apoA-I containing
post-translational modification of Tyr166 by nitration, we per-
formed surface plasmon resonance spectroscopy analyses. The
Kd values for the interaction between hLCAT and rHDL
formed with WT apoA-I versus NO2-Tyr166-apoA-I were
examined. Nitration of apoA-I Tyr166 had a dramatic effect on
HDL/hLCAT binding affinity, reducing the Kd of LCAT inter-
action with HDL generated from NO2-Tyr166-apoA-I by20-
fold compared with HDL fromWT apoA-I (Table 3).
Collectively, the data show that apoA-I Tyr166 modification
through nitration reduced the capacity to bind and activate
LCAT in vitro. However, no in vivo investigations with recom-
binant NO2-Tyr166-apoA-I have thus far been performed. The
reasons for this are severalfold. First, it has previously been
reported that mouse LCAT does not interact with human
apoA-I equivalently (36), and remarkably, Tyr166 is not con-
served inmouse apoA-I. Thus, to adequately examine the func-
tion of NO2-Tyr166-apoA-I in vivo, we needed to develop a
“humanized” model (i.e. human LCAT-containing) for investi-
gation of this uniquely human apoA-I residue. Second, recom-
binant NO2-Tyr166-apoA-I initially produced in typical labora-
tory strains of E. coli contains endotoxin and is not suitable for
in vivo studies. To overcome these obstacles in the present
study, we (i) generated hLCATTg/Tg, apoA-I/mice, enabling
FIGURE 4. SPR sensorgrams of recombinant nascent HDL forms with
LCAT.Goat anti-apoA-I antibodywas first immobilized on a CM5 sensor chip.
HDLs were captured on the sensor chip, and signals from a control flow cell
and from buffer runs were subtracted. A, SPR sensorgrams of interaction
between hLCAT and nascent HDL formed with recombinant WT apoA-I. The
concentrations of LCAT are shown. B, differential LCAT binding to HDLmade
of either WT apoA-I or apoA-I Y166A, Y166E, or Y192F mutants.
TABLE 2
Reaction kinetics of recombinant nascent HDL particles with LCAT
Apparent kinetic parameters for the interaction of recombinant human LCAT and
the indicated rHDL were determined as described under “Experimental Proce-
dures.” All values represent the mean  S.D. of results from three independent
determinations.
HDL
Apparent
Km
Apparent
Vmax
Apparent
Vmax/Km
Percentage of WT k
cat (Vmax/Km)
M nmol/h/g nmol/h/g/M %
WT 1.5 0.3 14.9 1.2 10.3 1.4 100
P165A 2.1 0.4 8.7 0.2 4.3 0.6 42
Y166F 10.0 1.3 12.0 0.8 1.2 0.1 12
Y166A 2.3 0.4 8.8 0.4 3.9 0.5 38
Y166E 2.0 0.7 15.4 1.8 7.9 1.8 77
Y166N 1.5 0.6 13.5 2.0 9.4 2.5 91
S167A 2.0 0.8 5.6 1.0 3.0 0.6 29
D168A 4.5 1.1 5.7 0.8 1.3 0.3 13
Y192F 2.4 0.6 16.8 0.5 7.2 1.7 70
Y192L 2.0 0.3 18.1 0.9 8.9 0.7 86
TABLE 3
Equilibriumconstantsof recombinanthumanLCATbinding toWTand
mutant recombinant apoA-I HDLs using surface plasmon resonance
spectrometry
Dissociation constants (Kd) of binding human LCAT to rHDL were determined as
described under “Experimental Procedures.” All values represent themean S.D. of
triplicate determinations.
HDL Kd
WT binding
affinity
M %
WT 1.4 0.3 100
P165A 3.9 0.7 36
Y166F 6.0 0.8 23
Y166A 6.4 0.5 22
Y166E 1.3 0.1 109
Y166N 1.0 0.1 140
Y166YNO2 30.0 0.7 5
S167A 2.6 0.4 54
D168A 7.5 1.0 19
Y192F 1.4 0.2 100
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studies of human apoA-I/LCAT interactions with injection of
recombinant human apoA-I forms, and (ii) generated endotox-
in-free recombinant human apoA-I forms using anE. coli strain
genetically modified to be functionally deficient in synthesis of
endotoxin, as described under “Experimental Procedures.”
Recombinant apoA-I proteins (NO2-Tyr166-apoA-I versus
apoA-I WT) were injected subcutaneously into hLCATTg/Tg,
apoA-I/ mice, and at the indicated times, we quantified the
HDL content of free cholesterol, total cholesterol, and choles-
teryl ester levels, as described under “Experimental Proce-
dures.” As shown in Fig. 5, no significant differences were
observed in free cholesterol levels inHDLparticles recovered at
baseline versus following NO2-Tyr166-apoA-I or apoA-I WT
injections. In contrast, both the cholesteryl ester and total cho-
lesterol contents of HDL increased after recombinant apoA-I
injections. More importantly, the cholesteryl ester level of
recovered HDL particles, a measure of in vivo LCAT activity,
showed significantly reduced increases after NO2-Tyr166-
apoA-I injection compared with apoA-I WT injection (Fig. 5).
Discussion
We previously identified a highly solvent-exposed peptide
region of apoA-I in nascent HDL using hydrogen-deuterium
exchange mass spectrometry and proposed that the region was
a protruding loop or solar flare-like structure that served as an
LCAT interaction site (24). However, the stability of the solar
flare region was challenged in a later published brief computa-
tional study (37), and an alternative investigation reported that
mutation of Tyr166, which is at the presumed tip of the protrud-
ing solar flare, produced only modest reduction of LCAT activ-
ity (13). Thus, the significance of both the solar flare region of
apoA-I in general and Tyr166 specifically as an interaction site
for LCAT docking and activation on the surface of nHDL has
been questioned. The recognition of Tyr166 as an abundant
post-translational modification to apoA-I within human ath-
erosclerotic plaque (26, 35), however, makes investigation of
the SF region of apoA-I in general and NO2-Tyr specifically of
importance.
In the present study, we systematically examined the roles of
individual amino acids in the SF loop region of apoA-I for their
potential involvement in LCAT binding and activation. Table 4
and Fig. 6 summarize the overall impact of apoA-I mutations
investigated in the present studies with respect to both LCAT
binding to nHDL and the ability to activate LCAT. They also
summarize proposed functional roles of the residues based on
the results obtained. An overwhelming finding of the present
studies is that site-specificmutation ofmultiple residues within
the SF region of apoA-I markedly impairs both the binding of
nHDL to LCAT and the ability of nHDL to activate LCAT.
Moreover, mutation of the same residues in the SF region failed
to adversely impact lipid binding (as judged by the comparable
chemical compositions of rHDL formed) and cholesterol efflux
activity of the apoA-I (as gauged by macrophage cholesterol
efflux activity measurements in the presence and absence of
ABCA1 stimulation).
There are several amino acids in the SF region of apoA-I that
are charged (Arg160, His162, Asp168, and Glu169) or bear a
hydroxyl group (Thr161, Tyr166, and Ser167) that could poten-
tially contribute to an ionic interaction or hydrogen bond for
intra- or interprotein interactions critical to the HDL/LCAT
reaction. Indeed, in modeling studies, we have suggested that
Arg160, His162, and Asp168 may interact with one another
through formation of a ternary salt bridge (24) (Fig. 6), provid-
ing the SF loop a measure of structural support, despite its
proposed solvent-exposed extended conformation. Further,
although mutations in apoA-I resulting in alterations in func-
tion are relatively rare, it is remarkable that naturally occurring
mutations to some of these SF residues with associated reduc-
FIGURE 5.HDL cholesterol levels before versus after recombinant apoA-I
injections. Plasma HDL free cholesterol (top), cholesteryl ester (middle), and
total cholesterol (bottom) levels were quantified in human hLCATTg/Tg, apoA-
I/mice before versus after subcutaneous injection of the indicated endo-
toxin-free recombinant apoA-I (WT versus NO2-Tyr
166-apoA-I; 4 mg/animal).
Serum samples were collected at the indicated time points. The LDL fraction
was precipitated, and then cholesterol and cholesteryl ester content of HDL
were quantified by stable isotope dilution gas chromatography with on-line
mass spectrometry, as described previously (28). Data shown represent the
mean S.D. of triplicate experiments.p valuesweredeterminedby Student’s
t test.
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tion in LCATactivity have been reported. For example, subjects
in families with either R160L (38) or H162Q (39) have been
reported with low HDL cholesterol levels and reduced LCAT
activation. Further, in one previous study of combined (double)
apoA-I mutants replacing a pair of charged amino acids, both
Arg160 andHis162, with non-polar amino acids (R160V/H162A)
produced an apoA-I form that showed a loss of LCAT activa-
tion similar to that of R160L and H162Q. Further, this double
mutant similarly did not show significant change in secondary
structure or lipid binding properties (40). Because we proposed
the existence of salt bridges between the basic residues Arg160
and His162 with Asp168 in the loop region (Fig. 6) (24, 31), we
expected thatmutation in Asp168 would also significantly affect
LCAT binding and activation (Table 4). Indeed, among all of
the mutants produced and examined in this study, D168A
exhibited the weakest LCATbinding affinity and themaximum
loss of LCAT catalytic efficacy. The results of the D168Amuta-
tion are thus consistent with the existence of a proposed salt
bridge in the SF loop region involving this residue. However, we
think it fair to comment that we still cannot exclude the possi-
bility that Asp168may be important inHDL/LCAT interactions
due to an alternative mechanism, such as through direct
involvement in an ionic interaction with LCAT.
The present studies further extend our investigation of
apoA-I Tyr166, a preferred site for myeloperoxidase- and nitric
oxide-catalyzed oxidative modification that is abundant in
human atherosclerotic plaque (25, 26). Because of prior con-
flicting results with the Y166F apoA-I mutant (34), in the pres-
ent study, we not only performedmore detailed enzyme kinetic
analyses of Y166F but also examined in detail other mutants,
including Y166A, Y166N, and Y166E, to more clearly define
structure/function requirements for LCAT interaction with
apoA-I Tyr166. rHDLs formed with either apoA-I mutant
Y166A or Y166F each showed significant impairment in acti-
vating LCAT activity, with corresponding reductions in bind-
ing affinity for LCAT. Of interest, substitutions of Tyr166 with
either Glu or Asn at this locus fully restored LCAT binding
capacity and nearly restored (70%) LCAT catalytic activity.
The observed LCAT binding and activation differences
between WT and Y166A/E/F/N mutants suggest the possible
existence of either ionic or hydrogen bond interaction of the
phenoxyl hydrogen of apoA-I Tyr166 with LCAT. Importantly,
our studies employing recombinant NO2-Tyr166-apoA-I show
a 20-fold reduction in Kd with LCAT in vitro and, within the
humanized model for studying apoA-I interaction with human
LCAT (the hLCATTg/Tg, apoA-I/ mouse), confirmed signif-
icant impairment in HDLmaturation rate with this post-trans-
lational modification (Fig. 5).
Most of themutations generated in this study are localized in
the SF region of apoA-I and not in presumed regions of apoA-I
linked to facilitating ABCA1 interaction, lipid binding, and cel-
lular cholesterol efflux. It has been reported that apoA-I region
63–73 and the carboxyl end of apoA-I are important for lipid-
free apoA-I-mediated cholesterol efflux, and the region 140–
150 is important for ABCG1-mediated cholesterol efflux (41,
42). All of the apoA-I mutants examined in this study showed
TABLE 4
Summary of the roles of amino acids in LCAT interaction loop of apoA-I
The presumed functions proposed for the apoA-I residues are speculative and are based on a combination of both site-specificmutagenesis/functional studies and structural
models of apoA-I reported in nHDL.
Amino acid in SF loop Presumed function
Mutations/post-translational
modification
Percentage of WT k
cat (Vmax/Km)
Percentage of WT
binding affinity
% %
Leu159 Structural L159Ra 2 NDb
Arg160 Salt bridge R160La 3–71 ND
His162 Salt bridge H162Qa 16 ND
Pro165 Structural P165Ra 38 ND
P165A 42 36
Tyr166 Hydrogen bond/polar interaction Y166F 12 23
Y166E 77 109
Y166N 91 140
Y166A 38 22
Y166YNO2c 55 5
Ser167 Hydrogen bond S167A 29 54
Asp168 Salt bridge D168A 13 19
a Familial mutations associated with low HDL in plasma and LCAT activity (38, 39, 45, 46).
bND, not determined.
c PTM identified in apoA-I from human aortic plaque (26, 35).
FIGURE 6. Schematic illustrating the amino acids in the solar flare region
ofapoA-I inHDL thataffect LCATactivationandHDL/LCATbindingaffin-
ity. Shown is a schematic of a highly solvent-exposed loop domain of apoA-I,
the so-called SF region, andmutations on each amino acid residue leading to
reduction in the catalytic efficiency of LCAT activation (filled arrow) and HDL/
LCAT binding affinity (open arrow). The post-translational modification at
Tyr166 also reduced the catalytic efficiency of LCAT activation and HDL/LCAT
binding affinity (box in the right corner). Previously proposed salt bridges
between Arg160, His162, and Asp168 are shown with a red dashed line.
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no significant impact onmacrophage cholesterol efflux activity.
Mutations in the loop region examined also did not affect the
overall lipid composition of rHDL formed, suggesting that
POPC and cholesterol binding properties of the mutants are
similar to those ofWT apoA-I (Table 1). The lack of changes in
cholesterol efflux function and the similar CD spectra and pre-
dicted-helicity of all of themutants examined further support
the contention that the overall secondary structures of apoA-I
in nHDL are not affected by point mutations in the SF region.
Indeed, our proposed structuralmodels of apoA-Iwithin nHDL
predict that residueswithin the SF region are not in an-helical
but rather a loop conformation with stability provided by a pair
of salt bridges with Asp168 (Fig. 6 and Table 4) (31, 43, 44).
Because CD spectroscopy is sensitive to -helical secondary
structure but is insensitive to random coil or loop structure
conformation, one would predict that mutations in the SF
region would not significantly affect the overall -helical con-
tent of apoA-I in nHDL as observed.
In conclusion, the data shown here are consistent with the SF
region of apoA-I serving as an important LCATdocking site for
nHDL that is also critical for appropriate lipid presentation and
catalytic efficiency for LCAT-catalyzed cholesterol esterifica-
tion. Moreover, in vivo studies using mice with humanized
HDL/LCAT interaction and injection of endotoxin-free recom-
binant human apoA-I harboring site-specific incorporation of
NO2-Tyr at position 166 confirm that this modified apoA-I
form is dysfunctional, showing impaired LCAT-mediatedHDL
maturation in vivo. The present studies thus suggest that efforts
to retard or block apoA-I modification at Tyr166 through either
MPO- or nitric oxide-derived oxidants may have potential util-
ity in preventing generation of a dysfunctional apoA-I or HDL
form in vivo during atherosclerosis.
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